Research location
Asheboro
North Carolina, United States
Advertisement
Research activity in Asheboro
North Carolina, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 147 trials and 161 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Asheboro
147 linked trials · page 1 of 3A Study of Modified Release RTN-001 In Patients With Uncontrolled HypertensionNCT07142356 · 2025-10-31 · 1 site observation
RECRUITING
E-Mindfulness Approaches for Living After Breast CancerNCT06748222 · 2025-06-27 · 1 site observation
RECRUITING
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsNCT06418204 · 2025-01-30 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 2 site observations
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerNCT05929768 · 2023-09-15 · 2 site observations
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 2 site observations
RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07 · 1 site observation
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 3 site observations
RECRUITING
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerNCT03851445 · 2019-02-06 · 3 site observations
RECRUITING
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE TrialNCT06216574 · 2024-03-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsNCT05896189 · 2024-02-29 · 2 site observations
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With AlbuminuriaNCT06150924 · 2023-12-14 · 1 site observation
COMPLETED
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionNCT06153693 · 2023-11-22 · 1 site observation
COMPLETED
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionNCT05968430 · 2023-07-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication RegimenNCT05769608 · 2023-03-13 · 1 site observation
COMPLETED
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 DiabetesNCT05254002 · 2022-06-23 · 1 site observation
COMPLETED
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT05096663 · 2022-03-15 · 1 site observation
ACTIVE_NOT_RECRUITING
An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the USNCT05097131 · 2021-11-18 · 1 site observation
TERMINATED
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD ParticipantsNCT05013008 · 2021-08-18 · 1 site observation
COMPLETED
Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled HypertensionNCT05001945 · 2021-07-01 · 1 site observation
COMPLETED
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT04625647 · 2021-04-16 · 3 site observations
ACTIVE_NOT_RECRUITING
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialNCT04457596 · 2021-03-02 · 3 site observations
ACTIVE_NOT_RECRUITING
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)NCT04268550 · 2020-04-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)NCT03811002 · 2019-07-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)NCT03971474 · 2019-05-28 · 1 site observation
COMPLETED
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With CancerNCT03939481 · 2019-05-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT03845296 · 2019-04-16 · 1 site observation
COMPLETED
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerNCT03199885 · 2019-04-05 · 1 site observation
TERMINATED
Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502NCT03609021 · 2019-02-26 · 1 site observation
TERMINATED
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerNCT03701334 · 2018-12-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung CancerNCT03382561 · 2018-05-21 · 1 site observation
COMPLETED
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerNCT03468985 · 2018-05-07 · 1 site observation
COMPLETED
Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and AlbuminuriaNCT03449199 · 2018-04-10 · 1 site observation
COMPLETED
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerNCT03373760 · 2017-11-30 · 1 site observation
COMPLETED
Understanding and Predicting Breast Cancer Events After TreatmentNCT02791581 · 2017-07-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic CancerNCT03180294 · 2017-05-31 · 1 site observation
COMPLETED
Phase 3 Randomized Placebo Controlled Clinical Trial of DonepezilNCT02822573 · 2017-05-30 · 1 site observation
COMPLETED
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)NCT03071692 · 2017-03-23 · 1 site observation
TERMINATED
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · 2017-03-03 · 1 site observation
COMPLETED
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNCT02954874 · 2017-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyNCT02927249 · 2017-01-06 · 1 site observation
TERMINATED
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise OnlyNCT02906930 · 2016-09-20 · 1 site observation
COMPLETED
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal ImpairmentNCT02827708 · 2016-09-20 · 1 site observation
COMPLETED
Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)NCT02595944 · 2016-07-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 DiabetesNCT02730377 · 2016-03-28 · 1 site observation
COMPLETED
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02785952 · 2015-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyNCT02445391 · 2015-10-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On MetforminNCT02554877 · 2015-10-01 · 1 site observation
COMPLETED
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney DiseaseNCT02540993 · 2015-09-17 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.